(NQ: )

N/A UNCHANGED

Last Price Updated: Add to My Watchlist

Price and Volume

Volume	0
Open	-
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	-
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	N/A
Dividend Yield	N/A

Chart for (: )

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

KYTHERA(R) Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss

September 22, 2015

Novel Oral Treatment Could Bring New Option to Large, Unsatisfied Market

KYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat

August 18, 2015

Submission Supported by Four Pivotal Phase III Trials Conducted in Europe and North America With More Than 1,500 Patients

Performance

More News

KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results and Progress Update

August 06, 2015

Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration

August 05, 2015

Allergan and KYTHERA Announce That Pending Transaction Will Now be for All-Cash Consideration

August 05, 2015

Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA

July 27, 2015

Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA

July 27, 2015

KYTHERA Biopharmaceuticals Announces Health Canada Authorization of BELKYRA(TM), a Submental Contouring Injectable Drug(i)

July 27, 2015

Watch List for Drug Manufacturers - Major Equities -- Pfizer, Bristol-Myers Squibb, Eli Lilly, Kythera Biopharma, and Impax Laboratories

July 20, 2015

Recapping My Most Atrocious Stock Picks of 2015

December 23, 2015

UPDATE 1-Allergan forecasts 2nd-half revenue above $8 bln

September 28, 2015

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.